

Date	Presenter	Title	Journal	Year	Vol	Page
2021/7/6	山田	Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients	Blood Adv	2021	5(12)	2624-2643
	加藤	Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study	Lancet Oncol	2021	22	765-768
2021/7/13	渡辺	Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience	J Clin Med	2021	10(8)	1684
	藤岡	臨床研究に関する説明				
2021/7/20	クリクラ	Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma	Blood	2021	137(22)	3027-3036
	今泉	JCOG報告会				
2021/7/27	古本	Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease	N Engl J Med	2020	382	1800-1810
	安東(北之園)	日本血液学会予行				
2021/9/7	一瀬	日本血液学会予行				
2021/9/14	勝岡	End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA	Blood Adv	2021	5(5)	1283-1290
	宮崎	Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer	Nat Genet	2021	53(7)	1088-1096
2021/9/21	糸永	留学報告				
2021/9/28	藤岡	Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies	Blood Adv	2020	4(3)	586-598
	佐藤	Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia.	N Engl J Med.	2021	385(10)	885-895
2021/10/5	西村	HTLV-1学会予行				
2021/10/12	今泉	HTLV-1学会予行				
2021/10/19	勝岡	日本内科学会九州地方会予行				
2021/10/26	加藤、糸永、佐藤、安東、澤山	日本血液学会予行報告会				
2021/11/2	坂本	Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial	Lancet Oncol	2021	22(5)	678-689
	宮崎、今泉	日本血液学会予行報告会				
2021/11/9	山田	Improved survival of patients with aggressive ATL by increased use of allo-HCT: a prospective observational study	Blood Adv	2021	5(20)	4156-4166
	長井	CAR-T療法の院内導入に関する説明				
2021/11/16	新山	日本輸血・細胞治療学会九州支部会 第68回総会・第89会例会 予行				
2021/11/30	渡辺	Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study	Blood	2021	138(16)	1429-1440
	澤山	Tisagenlecleucel Outcomes in Relapsed/Refractory Extramedullary ALL: A Pediatric Real World CAR Consortium Report(PMID: 34794180)	Blood Adv	2021		2021005564.